A phase 1 open label dose escalation study evaluate the safety of a single escalating dose of NX-CP105 (human adult bone marrow derived somatic cells [hABM-SC] administered by endomyocardial injection to cohorts of adults 30-60 days following acute myocardial infarction.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human adult bone marrow-derived somatic cell therapy Neuronyx (Primary)
Indications Myocardial infarction
Focus Adverse reactions

Most Recent Events

09 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
16 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight